Evidence map›Paper›PMID 36153506›Full record

ArticleDiagnostic pathology2022

DICER1-associated central nervous system sarcoma with neural lineage differentiation: a case report.

Kun Yao, Zejun Duan, Jing Feng, Changxiang Yan, Xueling Qi

Open access · goldAbstract readCase Reports
In one paragraph

Article in Diagnostic pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Rare child primary intracranial sarcoma associated with DICER1 mutation: a case report and review of the literature.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026
    Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Kun Yao *Department of Pathology, Sanbo Brain Hospital, Capital Medical University, No.50 Xiangshan Yikesong Road, Haidian District, 100093, Beijing, China.
Zejun Duan *Department of Pathology, Sanbo Brain Hospital, Capital Medical University, No.50 Xiangshan Yikesong Road, Haidian District, 100093, Beijing, China.
Jing FengDepartment of Pathology, Sanbo Brain Hospital, Capital Medical University, No.50 Xiangshan Yikesong Road, Haidian District, 100093, Beijing, China.
Changxiang YanDepartment of Neurosurgery, Sanbo Brain Hospital, Capital Medical University, 100093, Beijing, China.
Xueling QiDepartment of Pathology, Sanbo Brain Hospital, Capital Medical University, No.50 Xiangshan Yikesong Road, Haidian District, 100093, Beijing, China. xszqxl169@mail.ccmu.edu.cn.ORCID http://orcid.org/0000-0002-5787-4951
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDICER1-associated central nervous system sarcoma (DCS) without evidence of other cancer-related syndromes is rare. Though the morphology of DCS was highly variable, the immunophenotype was predominant myogenic phenotype. Other lineage markers were consistently negative. CASE PRESENTATION: We report a case of DCS with neurogenic differentiation proved by immunohistochemical staining and whole-exome sequencing (WES). An 8-year-old female patient presented with 8-day history of headache, nausea and vomiting. Magnetic resonance imaging (MRI) revealed a heterogeneous mass in the left parietal lobe. The patient underwent the craniotomy via left parietal approach to resect the tumor completely. Histologically, the tumor predominately showed fibrosarcoma-like spindle cells with obvious cytoplasmic eosinophilic globules. Immunohistochemically, the tumor stained positively for DICER1, Desmin, and several neurogenic markers. DICER1 somatic hotspot mutation was confirmed by WES, as well as TP53 and RAF1 mutations which were commonly found in DCS, and other sarcoma-associated genes including AR, AXL and ETV5 mutations. Subsequently, the result of Gene Ontology (GO) analysis showed that the mutated genes in this case were involved in neuron development. All of these findings indicated the diagnosis of DCS with neurogenic differentiation. Postoperatively, the patient received high-dose radiotherapy (60 Gy) and chemotherapy. There was no MRI evidence of tumor recurrence at the 21-month postoperative follow-up.

conclusionsThis unusual DCS case with neuronal differentiation is an important addition to the immuno-phenotypic spectrum of DCS. Although the prognosis for DCS is poor, gross tumor resection with high dose radiotherapy and chemotherapy may assist in prolonging survival.

Indexed as

Central Nervous System NeoplasmsSarcomaSoft Tissue NeoplasmsCentral Nervous SystemDEAD-box RNA HelicasesDesminFemaleHumansMutationNeoplasm Recurrence, LocalRibonuclease IIIDEAD-box RNA HelicasesDesminDICER1 protein, humanRibonuclease IIICase reportDICER1-associated central nervous system sarcomaNeurogenic differentiationRadiotherapyWhole-exome sequencing

Identifiers

PMID36153506
PMCPMC9508712
OpenAlexW4297186228

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.